To include your compound in the COVID-19 Resource Center, submit it here.

Alirocumab: Additional Phase III data

Additional data from the double-blind, international Phase III ODYSSEY LONG TERM safety trial in 2,341 patients with hypercholesterolemia and high cardiovascular risk who were not adequately controlled with lipid-lowering therapy showed

Read the full 318 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE